Research School of Biology, College of Medicine, Biology and Environment, The Australian National University, Canberra, Australian Capital Territory, Australia.
PLoS One. 2013;8(2):e54974. doi: 10.1371/journal.pone.0054974. Epub 2013 Feb 6.
Growth of the virulent human malaria parasite Plasmodium falciparum is dependent on an extracellular supply of pantothenate (vitamin B(5)) and is susceptible to inhibition by pantothenate analogues that hinder pantothenate utilization. In this study, on the hunt for pantothenate analogues with increased potency relative to those reported previously, we screened a series of pantothenamides (amide analogues of pantothenate) against P. falciparum and show for the first time that analogues of this type possess antiplasmodial activity. Although the active pantothenamides in this series exhibit only modest potency under standard in vitro culture conditions, we show that the potency of pantothenamides is selectively enhanced when the parasite culture medium is pre-incubated at 37°C for a prolonged period. We present evidence that this finding is linked to the presence in Albumax II (a serum-substitute routinely used for in vitro cultivation of P. falciparum) of pantetheinase activity: the activity of an enzyme that hydrolyzes the pantothenate metabolite pantetheine, for which pantothenamides also serve as substrates. Pantetheinase activity, and thereby pantothenamide degradation, is reduced following incubation of Albumax II-containing culture medium for a prolonged period at 37°C, revealing the true, sub-micromolar potency of pantothenamides. Importantly we show that the potent antiplasmodial effect of pantothenamides is attenuated with pantothenate, consistent with the compounds inhibiting parasite proliferation specifically by inhibiting pantothenate and/or CoA utilization. Additionally, we show that the pantothenamides interact with P. falciparum pantothenate kinase, the first enzyme involved in converting pantothenate to coenzyme A. This is the first demonstration of on-target antiplasmodial pantothenate analogues with sub-micromolar potency, and highlights the potential of pantetheinase-resistant pantothenamides as antimalarial agents.
疟原虫恶性生长依赖于细胞外泛酸(维生素 B(5))的供应,并且容易受到阻碍泛酸利用的泛酸类似物的抑制。在这项研究中,为了寻找比以前报道的更有效的泛酸类似物,我们对一系列泛酰氨(泛酸的酰胺类似物)进行了抗疟原虫筛选,并首次表明该类型的类似物具有抗疟原虫活性。虽然该系列中具有活性的泛酰氨在标准的体外培养条件下仅显示出适度的效力,但我们表明,当寄生虫培养基在 37°C 下长时间预孵育时,泛酰氨的效力会选择性增强。我们提供的证据表明,这一发现与 Albumax II(一种常用于体外培养疟原虫的血清替代物)中存在的泛酰氨酶活性有关:该酶可水解泛酸代谢物泛硫乙胺,而泛酰氨也是其底物。泛酰氨酶活性以及泛酰氨的降解,在 Albumax II 含培养基长时间 37°C 孵育后会降低,从而揭示了泛酰氨的真实、亚微摩尔效力。重要的是,我们表明,在存在泛酸的情况下,泛酰氨的强效抗疟原虫作用会减弱,这与这些化合物通过抑制泛酸和/或辅酶 A 的利用来特异性抑制寄生虫增殖的情况一致。此外,我们表明,泛酰氨与恶性疟原虫泛酸激酶相互作用,该酶是将泛酸转化为辅酶 A 的第一个酶。这是首次证明具有亚微摩尔效力的针对靶标抗疟原虫泛酸类似物,并且强调了抗泛酰氨酶泛酰氨类似物作为抗疟药物的潜力。